GeneTex

About GeneTex

GeneTex operates as a multinational biotechnology firm specializing in the manufacture and supply of bioreagents for the life sciences research community. The company was established in 1997 in San Antonio, Texas, by a group of distinguished scientists: Dr. Wen-Hwa Lee, Dr. Eva Y.-H. P. Lee, Dr. Joel B. Baseman, and Dr. C. Kent Osborne. The founders leveraged their deep expertise in oncology, cancer biology, and infectious diseases to address the scientific community's need for highly reliable antibodies, initially focusing on prognostic markers for breast cancer. Dr. Wen-Hwa Lee is recognized for discovering the retinoblastoma (Rb) tumor suppressor protein, while Dr. Eva Y. Lee co-discovered the Rb gene and is an authority on breast cancer genetics. Dr. C. Kent Osborne is a clinical oncologist focused on breast cancer treatment, and Dr. Joel B. Baseman is a prominent infectious disease researcher.

The business model centers on the development, manufacturing, licensing, and sale of a comprehensive catalog of research reagents. Its clientele consists of academic and industry investigators engaged in basic and translational biomedical research. GeneTex generates revenue through the direct sale of its products, which include primary and secondary antibodies, recombinant proteins, ELISA kits, cell lysates, and other research tools. The company serves a global market, with key operational milestones including the establishment of a production facility in Taiwan in 2007 to scale up manufacturing, relocating its U.S. headquarters to Irvine, California, in 2009 to be closer to a major biotech hub, and opening new facilities for recombinant antibody and protein production in 2020.

GeneTex's core offering is its extensive portfolio of antibodies and related reagents that cover a wide range of research fields like cancer, neuroscience, immunology, and cell biology. A key differentiator is the company's commitment to rigorous product validation to combat the issue of unreliable and non-specific antibodies in the research market. In 2016, GeneTex joined the International Working Group on Antibody Validation (IWGAV) and implemented an enhanced "Five-Pillar Validation" methodology. This process verifies antibody specificity and performance using techniques such as genetic strategies (knockout/knockdown), orthogonal validation, and recombinant expression. The firm has also heavily invested in recombinant monoclonal antibody technology, which offers superior lot-to-lot consistency and can be developed rapidly. This focus ensures that researchers receive dependable reagents to produce accurate and reproducible data.